生物制药是中国和欧美国家差距较小的战略性新兴产业,是赶超世界最有潜力的领域。虽然中国现在已经是世界第二大经济强国,但目前仍没有把生物医药纳入支柱性产业,国家在下一步的“十三五”规划中,必须对此有足够的重视。细胞培养基是发展生物制药的核心技术生物制药和传统医药的最大区别在于生物制药的生产工艺。生物制药是依靠重组DNA的技术来生产药品。再好的生物医药,例如单克隆抗体、激素或者生长因子,也是依靠重组DNA的技术放入细胞中,以细胞作为生产的工 Biopharmaceuticals is a strategic emerging industry with a small gap between China and Europe and the United States and is the most potential area for catching up and surpassing the world. Although China is now the second largest economic power in the world, biopharmaceuticals are still not included in the pillar industries. Therefore, the country must pay enough attention to this in the next “13th Five-Year Plan.” Cell culture medium is the core technology for the development of biopharmaceuticals The biggest difference between biopharmaceutical and traditional medicine lies in the biopharmaceutical manufacturing process. Biopharmaceutical relies on the technology of recombinant DNA to produce medicines. Even the best biopharmaceuticals, such as monoclonal antibodies, hormones or growth factors, are also put into cells by means of recombinant DNA technology, using cells as a producer